The abnormal activation of the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome is a major contributor to the development of chronic colitis, and therapeutic interventions targeting NLRP3 have demonstrated significant efficacy in delaying or preventing disease onset [7]. This evidence concerns the gene NLRP3 and Chronic colitis.